fluphenazine (permitil) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Fluphenazine is a trifluoro-methyl phenothiazine derivative intended for the management of schizophrenia and other psychotic disorders. Fluphenazine has not been shown effective in the management of behaviorial complications in patients with mental retardation. Fluphenazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis.   NCATS

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Missing data
  • Pro Drug: No

Drug Pricing (per unit)

United States

$0.3227 - $75.2600
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

10-(3-(2-hydroxyethyl)piperazinopropyl)-2-(trifluoromethyl)phenothiazine | 10-(3'-(4''-(beta-hydroxyethyl)-1''-piperazinyl)-propyl)-3-trifluoromethylphenothiazine | 1-(2-hydroxyethyl)-4-(3-(trifluoromethyl-10-phenothiazinyl)propyl)-piperazine | 2-(4-(3-[2-(trifluoromethyl)-10h-phenothiazin-10-yl]propyl)-1-piperazinyl)ethanol | 2-(trifluoromethyl)-10-(3-(1-(beta-hydroxyethyl)-4-piperazinyl)propyl)phenothiazine | 4-(3-(2-(trifluoromethyl)-10h-phenothiazin-10-yl)propyl)-1-piperazineethanol | 4-(3-(2-trifluoromethyl-10-phenothiazyl)-propyl)-1-piperazineethanol | 4-(3-(-trifluoromethyl-10-phenothiazyl)-propyl)-1-piperazineethanol | decazate | flufenazin | flufenazina | flufenazine decanoate | fluorfenazine | fluorophenazine | fluorophenazine decanoate | fluorphenazine | fluphenazin | fluphenazine | fluphénazine | fluphenazine decanoate | fluphenazine depot | fluphenazine dihydrochloride | fluphenazine enantate | fluphenazine enanthate | fluphenazine hcl | fluphenazine hydrochloride | fluphenazine maleate | fluphenazinum | ftorphenazine | ftorphenazine decanoate | liogen | lyogen | mirenil | modecate | modecate conc | moditen | moditen depot | moditen-depot | moditen enant | moditen enanthate | permitil | phthorphenazine | prolixin | prolixin decanoate | prolixin enanthate | triflumethazine

Organizations (48)

Research & Development (9)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (39)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (10)

Approved Indications (2)


 

Psychotic Disorders

Schizophrenia (approved 1987)

Experimental Indications - Clinical Trial Phases 1-4 (10)


 

Anxiety Disorders (Phase 3)

Dementia (Phase 3)

Depression (Phase 3)

Gambling (Phase 2)

Multiple Myeloma (Phase 1/Phase 2)

Psoriasis (Phase 2)

Psychophysiologic Disorders (Phase 3)

Psychotic Disorders (Phase 4)

Schizophrenia (Phase 4)

Schizophrenia Spectrum and Other Psychotic Disorders (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 9
  • # of Trial Organizations: 9

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue